Individual variation in the response to drug therapy has been mainly attributed to the genetic polymorphism of cytochrome P 450 isoenzymes. Mutation in the gene CYP2C19 （cytochrome P450 2C19） has been shown to influ...Individual variation in the response to drug therapy has been mainly attributed to the genetic polymorphism of cytochrome P 450 isoenzymes. Mutation in the gene CYP2C19 （cytochrome P450 2C19） has been shown to influence the clinical efficiency of clopidogrel. The aim is to investigate the frequencies of CYP2C19＊2 （c.G681A; rs4244285）, CYP2C19＊3 （c.G636A; rs4986893）, CYP2C19＊17 （c.C806T; rs12248560） and to compare the allele and genotype frequencies of CYP2C19＊2 in patients with CHD （coronary heart disease） to healthy volunteers. We examined 53 patients with CHD received clopidogrel and 146 healthy volunteers. CYP2C19＊2, CYP2C19＊3, CYP2C19＊17 carriages were determined by a polymerase-chain reaction. The observed genotype distribution did not deviate from Hardy-Weinberg equilibrium, it was determined by a Chi-square test with Yates correction. The frequency of CYP2C19＂2 allele reported in patients with CHD and in the healthy volunteers was 16.6% and 13.3%, respectively （P = 0.584）. The results of the present study may be helpful in developing current and future directions for its management.展开更多
文摘Individual variation in the response to drug therapy has been mainly attributed to the genetic polymorphism of cytochrome P 450 isoenzymes. Mutation in the gene CYP2C19 （cytochrome P450 2C19） has been shown to influence the clinical efficiency of clopidogrel. The aim is to investigate the frequencies of CYP2C19＊2 （c.G681A; rs4244285）, CYP2C19＊3 （c.G636A; rs4986893）, CYP2C19＊17 （c.C806T; rs12248560） and to compare the allele and genotype frequencies of CYP2C19＊2 in patients with CHD （coronary heart disease） to healthy volunteers. We examined 53 patients with CHD received clopidogrel and 146 healthy volunteers. CYP2C19＊2, CYP2C19＊3, CYP2C19＊17 carriages were determined by a polymerase-chain reaction. The observed genotype distribution did not deviate from Hardy-Weinberg equilibrium, it was determined by a Chi-square test with Yates correction. The frequency of CYP2C19＂2 allele reported in patients with CHD and in the healthy volunteers was 16.6% and 13.3%, respectively （P = 0.584）. The results of the present study may be helpful in developing current and future directions for its management.
